Semaglutide in-SITU GEL formulation for parenteral administration

The in-situ gel formulation using Poloxamer polymers addresses the inconvenience of long-term semaglutide injections by providing controlled, sustained release and improved stability, enhancing patient compliance and treatment efficacy.

WO2026154372A1PCT designated stage Publication Date: 2026-07-23EMCURE PHARMACEUTICALS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
EMCURE PHARMACEUTICALS LTD
Filing Date
2026-01-14
Publication Date
2026-07-23

AI Technical Summary

Technical Problem

Existing long-term semaglutide injection formulations are inconvenient and uncomfortable, leading to poor patient compliance, and existing slow-release formulations lack controlled initial release and manufacturing efficiency.

Method used

A long-acting in-situ gel formulation using poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) polymers, such as Poloxamer, which forms a gel upon contact with body fluids, providing controlled release of semaglutide for extended periods.

Benefits of technology

The formulation offers high bioavailability, enhanced safety, storage stability, and cost-effectiveness with sustained release of semaglutide for at least 10 hours, maintaining effective plasma concentrations for up to 14 days.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000002_0001
    Figure IMGF000002_0001
  • Figure IMGF000008_0001_TABLE
    Figure IMGF000008_0001_TABLE
  • Figure IMGF000009_0001_TABLE
    Figure IMGF000009_0001_TABLE
Patent Text Reader

Abstract

The present invention relates to a long-acting in-situ gel formulation comprising semaglutide for parenteral administration.
Need to check novelty before this filing date? Find Prior Art